The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morgan, D. J.
Right arrow Articles by Sherman, L. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morgan, D. J.
Right arrow Articles by Sherman, L. A.
The Journal of Immunology, 1998, 160: 643-651.
Copyright © 1998 by The American Association of Immunologists

Activation of Low Avidity CTL Specific for a Self Epitope Results in Tumor Rejection But Not Autoimmunity1

David J. Morgan*, Huub T. C. Kreuwel*, Shonna Fleck*, Hyam I. Levitsky{dagger}, Drew M. Pardoll{dagger} and Linda A. Sherman2,*

* Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037; and {dagger} Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205

To determine how self-tolerance can alter the ability of the immune system to respond against tumor-associated Ags that are also expressed by normal tissue, we designed experiments in which the same protein was expressed both as a tumor Ag and as a transgene product. Unlike conventional BALB/c mice that rejected renal carcinoma cells transfected with the influenza virus hemagglutinin (Renca-HA), transgenic mice that are tolerant of HA due to its expression as a self-Ag on pancreatic islet ß cells, (Ins-HA mice) supported progressive growth of these tumor cells. However, when Ins-HA mice were immunized with a recombinant strain of vaccinia virus expressing the dominant H-2Kd peptide epitope of HA before receiving Renca-HA cells, they too were able to reject the tumor cells. Rejection of Renca-HA cells by immunized Ins-HA mice was found to be associated with the generation of CTL having much lower avidity for target cells presenting the KdHA epitope than CTL from immunized conventional BALB/c mice. Significantly, we show that self-tolerance to the HA Ag is quantitative rather then absolute, and that vaccination of Ins-HA mice can activate low avidity KdHA-specific CD8+ T cells that are able to reject tumor cells expressing high levels of HA, yet these mice remain tolerant of pancreatic islet ß cells expressing HA.




This article has been cited by other articles:


Home page
Cancer Res.Home page
A. Shanker, A. D. Brooks, K. M. Jacobsen, J. W. Wine, R. H. Wiltrout, H. Yagita, and T. J. Sayers
Antigen Presented by Tumors In vivo Determines the Nature of CD8+ T-Cell Cytotoxicity
Cancer Res., August 15, 2009; 69(16): 6615 - 6623.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
M. J. Turner, E. R. Jellison, E. G. Lingenheld, L. Puddington, and L. Lefrancois
Avidity maturation of memory CD8 T cells is limited by self-antigen expression
J. Exp. Med., August 4, 2008; 205(8): 1859 - 1868.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
J. McGill, N. Van Rooijen, and K. L. Legge
Protective influenza-specific CD8 T cell responses require interactions with dendritic cells in the lungs
J. Exp. Med., July 7, 2008; 205(7): 1635 - 1646.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
B. Bolinger, P. Krebs, Y. Tian, D. Engeler, E. Scandella, S. Miller, D. C. Palmer, N. P. Restifo, P.-A. Clavien, and B. Ludewig
Immunologic ignorance of vascular endothelial cells expressing minor histocompatibility antigen
Blood, May 1, 2008; 111(9): 4588 - 4595.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. E. Rolle, R. Carrio, and T. R. Malek
Modeling the CD8+ T Effector to Memory Transition in Adoptive T-Cell Antitumor Immunotherapy
Cancer Res., April 15, 2008; 68(8): 2984 - 2992.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. N. Janicki, S. R. Jenkinson, N. A. Williams, and D. J. Morgan
Loss of CTL Function among High-Avidity Tumor-Specific CD8+ T Cells following Tumor Infiltration
Cancer Res., April 15, 2008; 68(8): 2993 - 3000.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. L. VanOosten and T. S. Griffith
Activation of Tumor-Specific CD8+ T Cells after Intratumoral Ad5-TRAIL/CpG Oligodeoxynucleotide Combination Therapy
Cancer Res., December 15, 2007; 67(24): 11980 - 11990.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. K. Bunt, L. Yang, P. Sinha, V. K. Clements, J. Leips, and S. Ostrand-Rosenberg
Reduced Inflammation in the Tumor Microenvironment Delays the Accumulation of Myeloid-Derived Suppressor Cells and Limits Tumor Progression
Cancer Res., October 15, 2007; 67(20): 10019 - 10026.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Weinhold, D. Sommermeyer, W. Uckert, and T. Blankenstein
Dual T Cell Receptor Expressing CD8+ T Cells with Tumor- and Self-Specificity Can Inhibit Tumor Growth without Causing Severe Autoimmunity
J. Immunol., October 15, 2007; 179(8): 5534 - 5542.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. Harari, C. Cellerai, F. B. Enders, J. Kostler, L. Codarri, G. Tapia, O. Boyman, E. Castro, S. Gaudieri, I. James, et al.
Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype
PNAS, October 9, 2007; 104(41): 16233 - 16238.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
B. J. E. Raveney and D. J. Morgan
Dynamic Control of Self-Specific CD8+ T Cell Responses via a Combination of Signals Mediated by Dendritic Cells
J. Immunol., September 1, 2007; 179(5): 2870 - 2879.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Werner-Klein, C. Dresch, P. Marconi, and T. Brocker
Transcriptional Targeting of B Cells for Induction of Peripheral CD8 T Cell Tolerance
J. Immunol., June 15, 2007; 178(12): 7738 - 7746.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Nair, D. Boczkowski, M. Fassnacht, D. Pisetsky, and E. Gilboa
Vaccination against the Forkhead Family Transcription Factor Foxp3 Enhances Tumor Immunity
Cancer Res., January 1, 2007; 67(1): 371 - 380.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
P. Otahal, T. D. Schell, S. C. Hutchinson, B. B. Knowles, and S. S. Tevethia
Early Immunization Induces Persistent Tumor-Infiltrating CD8+ T Cells against an Immunodominant Epitope and Promotes Lifelong Control of Pancreatic Tumor Progression in SV40 Tumor Antigen Transgenic Mice.
J. Immunol., September 1, 2006; 177(5): 3089 - 3099.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. Singh and Y. Paterson
Vaccination Strategy Determines the Emergence and Dominance of CD8+ T-Cell Epitopes in a FVB/N Rat HER-2/neu Mouse Model of Breast Cancer.
Cancer Res., August 1, 2006; 66(15): 7748 - 7757.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. A. McWilliams, S. M. McGurran, S. W. Dow, J. E. Slansky, and R. M. Kedl
A Modified Tyrosinase-Related Protein 2 Epitope Generates High-Affinity Tumor-Specific T Cells but Does Not Mediate Therapeutic Efficacy in an Intradermal Tumor Model
J. Immunol., July 1, 2006; 177(1): 155 - 161.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. M. Ryan and T. D. Schell
Accumulation of CD8+ T Cells in Advanced-Stage Tumors and Delay of Disease Progression following Secondary Immunization against an Immunorecessive Epitope
J. Immunol., July 1, 2006; 177(1): 255 - 267.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. D. Gritzapis, L. G. Mahaira, S. A. Perez, N. T. Cacoullos, M. Papamichail, and C. N. Baxevanis
Vaccination with Human HER-2/neu (435-443) CTL Peptide Induces Effective Antitumor Immunity against HER-2/neu-Expressing Tumor Cells In vivo.
Cancer Res., May 15, 2006; 66(10): 5452 - 5460.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. K. Bunt, P. Sinha, V. K. Clements, J. Leips, and S. Ostrand-Rosenberg
Inflammation Induces Myeloid-Derived Suppressor Cells that Facilitate Tumor Progression
J. Immunol., January 1, 2006; 176(1): 284 - 290.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
K. Liu, J. Idoyaga, A. Charalambous, S.-i. Fujii, A. Bonito, J. Mordoh, R. Wainstok, X.-F. Bai, Y. Liu, and R. M. Steinman
Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells
J. Exp. Med., December 5, 2005; 202(11): 1507 - 1516.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
K. R. Ryan, D. McCue, and S. M. Anderton
Fas-mediated death and sensory adaptation limit the pathogenic potential of autoreactive T cells after strong antigenic stimulation
J. Leukoc. Biol., July 1, 2005; 78(1): 43 - 50.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. Steinaa, P. B. Rasmussen, A. M. Wegener, L. Sonderbye, D. R. Leach, J. Rygaard, S. Mouritsen, and A. M. Gautam
Linked Foreign T-Cell Help Activates Self-Reactive CTL and Inhibits Tumor Growth
J. Immunol., July 1, 2005; 175(1): 329 - 334.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
A. M. Ercolini, B. H. Ladle, E. A. Manning, L. W. Pfannenstiel, T. D. Armstrong, J.-P. H. Machiels, J. G. Bieler, L. A. Emens, R. T. Reilly, and E. M. Jaffee
Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response
J. Exp. Med., May 16, 2005; 201(10): 1591 - 1602.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. A. Lyman, C. T. Nugent, K. L. Marquardt, J. A. Biggs, E. G. Pamer, and L. A. Sherman
The Fate of Low Affinity Tumor-Specific CD8+ T Cells in Tumor-Bearing Mice
J. Immunol., March 1, 2005; 174(5): 2563 - 2572.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
G. Zhou, Z. Lu, J. D. McCadden, H. I. Levitsky, and A. L. Marson
Reciprocal Changes in Tumor Antigenicity and Antigen-specific T Cell Function during Tumor Progression
J. Exp. Med., December 20, 2004; 200(12): 1581 - 1592.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
G. R. Leggatt, S. Narayan, G. J. P. Fernando, and I. H. Frazer
Changes to peptide structure, not concentration, contribute to expansion of the lowest avidity cytotoxic T lymphocytes
J. Leukoc. Biol., October 1, 2004; 76(4): 787 - 795.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
W. C. Bartholomae, F. H. Rininsland, J. C. Eisenberg, B. O. Boehm, P. V. Lehmann, and M. Tary-Lehmann
T Cell Immunity Induced by Live, Necrotic, and Apoptotic Tumor Cells
J. Immunol., July 15, 2004; 173(2): 1012 - 1022.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. W. Lawrence and T. J. Braciale
Activation, Differentiation, and Migration of Naive Virus-Specific CD8+ T Cells during Pulmonary Influenza Virus Infection
J. Immunol., July 15, 2004; 173(2): 1209 - 1218.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. A. Mihalyo, A. D. H. Doody, J. P. McAleer, E. C. Nowak, M. Long, Y. Yang, and A. J. Adler
In Vivo Cyclophosphamide and IL-2 Treatment Impedes Self-Antigen-Induced Effector CD4 Cell Tolerization: Implications for Adoptive Immunotherapy
J. Immunol., May 1, 2004; 172(9): 5338 - 5345.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. Y. Mapara and M. Sykes
Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance
J. Clin. Oncol., March 15, 2004; 22(6): 1136 - 1151.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
A. Vogt, P.-T. Chuang, J. Hebert, J. Hwang, Y. Lu, L. Kopelovich, M. Athar, D. R. Bickers, and E. H. Epstein Jr.
Immunoprevention of Basal Cell Carcinomas with Recombinant Hedgehog-interacting Protein
J. Exp. Med., March 15, 2004; 199(6): 753 - 761.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
T. D. Schell
In Vivo Expansion of the Residual Tumor Antigen-Specific CD8+ T Lymphocytes That Survive Negative Selection in Simian Virus 40 T-Antigen-Transgenic Mice
J. Virol., February 15, 2004; 78(4): 1751 - 1762.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. Lane, J. Leitch, X. Tan, J. Hadjati, J. L. Bramson, and Y. Wan
Vaccination-Induced Autoimmune Vitiligo Is a Consequence of Secondary Trauma to the Skin
Cancer Res., February 15, 2004; 64(4): 1509 - 1514.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Cuenca, F. Cheng, H. Wang, J. Brayer, P. Horna, L. Gu, H. Bien, I. M. Borrello, H. I. Levitsky, and E. M. Sotomayor
Extra-Lymphatic Solid Tumor Growth Is Not Immunologically Ignored and Results in Early Induction of Antigen-Specific T-Cell Anergy: Dominant Role of Cross-Tolerance to Tumor Antigens
Cancer Res., December 15, 2003; 63(24): 9007 - 9015.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. J. Young, L. S. Kay, M. J. Phillips, and L. Zhang
Antitumor Activity Mediated by Double-Negative T Cells
Cancer Res., November 15, 2003; 63(22): 8014 - 8021.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. Cuadros, A. L. Dominguez, G. I. Frost, P. Borgstrom, and J. Lustgarten
Cooperative Effect between Immunotherapy and Antiangiogenic Therapy Leads to Effective Tumor Rejection in Tolerant Her-2/neu Mice
Cancer Res., September 15, 2003; 63(18): 5895 - 5901.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Li, W. Li, S. Liang, D. Cai, M. P. Kieny, L. Jacob, A. Linnenbach, J. W. Abramczuk, H. Bender, K. Sproesser, et al.
Recombinant CD63/ME491/Neuroglandular/NKI/C-3 Antigen Inhibits Growth of Established Tumors in Transgenic Mice
J. Immunol., September 15, 2003; 171(6): 2922 - 2929.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Azuma, T. Takahashi, A. Kunisato, T. Kitamura, and H. Hirai
Human CD4+ CD25+ Regulatory T Cells Suppress NKT Cell Functions
Cancer Res., August 1, 2003; 63(15): 4516 - 4520.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Schroers, L. Shen, L. Rollins, Z. Xiao, G. Sonderstrup, K. Slawin, X. F. Huang, and S.-Y. Chen
Identification of MHC Class II-restricted T-cell Epitopes in Prostate-specific Membrane Antigen
Clin. Cancer Res., August 1, 2003; 9(9): 3260 - 3271.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. W. Hodge, D. W. Grosenbach, W. M. Aarts, D. J. Poole, and J. Schlom
Vaccine Therapy of Established Tumors in the Absence of Autoimmunity
Clin. Cancer Res., May 1, 2003; 9(5): 1837 - 1849.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. P. Rubinstein, A. N. Kadima, M. L. Salem, C. L. Nguyen, W. E. Gillanders, M. I. Nishimura, and D. J. Cole
Transfer of TCR Genes into Mature T Cells Is Accompanied by the Maintenance of Parental T Cell Avidity
J. Immunol., February 1, 2003; 170(3): 1209 - 1217.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. E. Touloukian, W. W. Leitner, R. E. Schnur, P. F. Robbins, Y. Li, S. Southwood, A. Sette, S. A. Rosenberg, and N. P. Restifo
Normal Tissue Depresses While Tumor Tissue Enhances Human T Cell Responses In Vivo to a Novel Self/Tumor Melanoma Antigen, OA1
J. Immunol., February 1, 2003; 170(3): 1579 - 1585.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
B. Yu, S. Kusmartsev, F. Cheng, M. Paolini, Y. Nefedova, E. Sotomayor, and D. Gabrilovich
Effective Combination of Chemotherapy and Dendritic Cell Administration for the Treatment of Advanced-Stage Experimental Breast Cancer
Clin. Cancer Res., January 1, 2003; 9(1): 285 - 294.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Castilleja, D. Carter, C. L. Efferson, N. E. Ward, K. Kawano, B. Fisk, A. P. Kudelka, D. M. Gershenson, J. L. Murray, C. A. O'Brian, et al.
Induction of Tumor-Reactive CTL by C-Side Chain Variants of the CTL Epitope HER-2/neu Protooncogene (369-377) Selected by Molecular Modeling of the Peptide: HLA-A2 Complex
J. Immunol., October 1, 2002; 169(7): 3545 - 3554.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. D. Higgins, M. A. Mihalyo, and A. J. Adler
Effector CD4 Cells Are Tolerized Upon Exposure to Parenchymal Self-Antigen
J. Immunol., October 1, 2002; 169(7): 3622 - 3629.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. A. Lawendowski, G. M. Giurleo, Y. Y. Huang, G. J. Franklin, J. M. Kaplan, B. L. Roberts, and C. A. Nicolette
Solid-Phase Epitope Recovery: A High Throughput Method for Antigen Identification and Epitope Optimization
J. Immunol., September 1, 2002; 169(5): 2414 - 2421.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
J. Hernandez, S. Aung, K. Marquardt, and L. A. Sherman
Uncoupling of Proliferative Potential and Gain of Effector Function by CD8+ T Cells Responding to Self-Antigens
J. Exp. Med., August 5, 2002; 196(3): 323 - 333.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
C. Ohlen, M. Kalos, L. E. Cheng, A. C. Shur, D. J. Hong, B. D. Carson, N. C.T. Kokot, C. G. Lerner, B. D. Sather, E. S. Huseby, et al.
CD8+ T Cell Tolerance to a Tumor-associated Antigen Is Maintained at the Level of Expansion Rather than Effector Function
J. Exp. Med., June 3, 2002; 195(11): 1407 - 1418.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J.-Y. Sun, R. S. Krouse, S. J. Forman, D. Senitzer, I. Sniecinski, S. Chatterjee, and K. K. Wong Jr.
Immunogenicity of a p210BCR-ABL Fusion Domain Candidate DNA Vaccine Targeted to Dendritic Cells by a Recombinant Adeno-associated Virus Vector in Vitro
Cancer Res., June 1, 2002; 62(11): 3175 - 3183.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. Schroers, X. F. Huang, J. Hammer, J. Zhang, and S.-Y. Chen
Identification of HLA DR7-restricted Epitopes from Human Telomerase Reverse Transcriptase Recognized by CD4+ T-Helper Cells
Cancer Res., May 1, 2002; 62(9): 2600 - 2605.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. M. zum Buschenfelde, C. Hermann, B. Schmidt, C. Peschel, and H. Bernhard
Antihuman Epidermal Growth Factor Receptor 2 (HER2) Monoclonal Antibody Trastuzumab Enhances Cytolytic Activity of Class I-restricted HER2-specific T Lymphocytes Against HER2-overexpressing Tumor Cells
Cancer Res., April 1, 2002; 62(8): 2244 - 2247.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
L. T. Nguyen, A. R. Elford, K. Murakami, K. M. Garza, S. P. Schoenberger, B. Odermatt, D. E. Speiser, and P. S. Ohashi
Tumor Growth Enhances Cross-Presentation Leading to Limited T Cell Activation without Tolerance
J. Exp. Med., February 11, 2002; 195(4): 423 - 435.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. A. Cordaro, K. E. de Visser, F. H. Tirion, T. N. M. Schumacher, and A. M. Kruisbeek
Can the Low-Avidity Self-Specific T Cell Repertoire Be Exploited for Tumor Rejection?
J. Immunol., January 15, 2002; 168(2): 651 - 660.
[Abstract] [Full Text] [PDF]


Home page
Br. J. Radiol.Home page
A C Armstrong and R E Hawkins
Vaccines in oncology: background and clinical potential
Br. J. Radiol., November 1, 2001; 74(887): 991 - 1002.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. E. de Visser, T. A. Cordaro, H. W. H. G. Kessels, F. H. Tirion, T. N. M. Schumacher, and A. M. Kruisbeek
Low-Avidity Self-Specific T Cells Display a Pronounced Expansion Defect That Can Be Overcome by Altered Peptide Ligands
J. Immunol., October 1, 2001; 167(7): 3818 - 3828.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
J. Hernandez, S. Aung, W. L. Redmond, and L. A. Sherman
Phenotypic and Functional Analysis of Cd8+ T Cells Undergoing Peripheral Deletion in Response to Cross-Presentation of Self-Antigen
J. Exp. Med., September 17, 2001; 194(6): 707 - 718.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. G. Cawthon, H. Lu, and M. A. Alexander-Miller
Peptide Requirement for CTL Activation Reflects the Sensitivity to CD3 Engagement: Correlation with CD8{alpha}{beta} Versus CD8{alpha}{alpha} Expression
J. Immunol., September 1, 2001; 167(5): 2577 - 2584.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. Meyer zum Buschenfelde, J. Metzger, C. Hermann, N. Nicklisch, C. Peschel, and H. Bernhard
The Generation of Both T Killer and Th Cell Clones Specific for the Tumor-Associated Antigen HER2 Using Retrovirally Transduced Dendritic Cells
J. Immunol., August 1, 2001; 167(3): 1712 - 1719.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. R. Riddell
Progress in cancer vaccines by enhanced self-presentation
PNAS, July 31, 2001; 98(16): 8933 - 8935.
[Full Text] [PDF]


Home page
J. Immunol.Home page
H. T. C. Kreuwel, J. A. Biggs, I. M. Pilip, E. G. Pamer, D. Lo, and L. A. Sherman
Defective CD8+ T Cell Peripheral Tolerance in Nonobese Diabetic Mice
J. Immunol., July 15, 2001; 167(2): 1112 - 1117.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. C. Eck and L. A. Turka
Adoptive Transfer Enables Tumor Rejection Targeted against a Self-Antigen without the Induction of Autoimmunity
Cancer Res., April 1, 2001; 61(7): 3077 - 3083.
[Abstract] [Full Text]


Home page
J. Immunol.Home page
J. Hernandez, A. Ko, and L. A. Sherman
CTLA-4 Blockade Enhances the CTL Responses to the p53 Self-Tumor Antigen
J. Immunol., March 15, 2001; 166(6): 3908 - 3914.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
J. M. Moser, J. D. Altman, and A. E. Lukacher
Antiviral Cd8+ T Cell Responses in Neonatal Mice: Susceptibility to Polyoma Virus-Induced Tumors Is Associated with Lack of Cytotoxic Function by Viral Antigen-Specific T Cells
J. Exp. Med., March 5, 2001; 193(5): 595 - 606.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. Ohlen, M. Kalos, D. J. Hong, A. C. Shur, and P. D. Greenberg
Expression of a Tolerizing Tumor Antigen in Peripheral Tissue Does Not Preclude Recovery of High-Affinity CD8+ T Cells or CTL Immunotherapy of Tumors Expressing the Antigen
J. Immunol., February 15, 2001; 166(4): 2863 - 2870.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. D. Sette, C. Oseroff, J. Sidney, J. Alexander, R. W. Chesnut, K. Kakimi, L. G. Guidotti, and F. V. Chisari
Overcoming T Cell Tolerance to the Hepatitis B Virus Surface Antigen in Hepatitis B Virus-Transgenic Mice
J. Immunol., January 15, 2001; 166(2): 1389 - 1397.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
E. M. Hiltbold, A. M. Vlad, P. Ciborowski, S. C. Watkins, and O. J. Finn
The Mechanism of Unresponsiveness to Circulating Tumor Antigen MUC1 Is a Block in Intracellular Sorting and Processing by Dendritic Cells
J. Immunol., October 1, 2000; 165(7): 3730 - 3741.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
P. Mukherjee, A. R. Ginardi, C. S. Madsen, C. J. Sterner, M. C. Adriance, M. J. Tevethia, and S. J. Gendler
Mice with Spontaneous Pancreatic Cancer Naturally Develop MUC-1-Specific CTLs That Eradicate Tumors When Adoptively Transferred
J. Immunol., September 15, 2000; 165(6): 3451 - 3460.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. T. Reilly, M. B. C. Gottlieb, A. M. Ercolini, J.-P. H. Machiels, C. E. Kane, F. I. Okoye, W. J. Muller, K. H. Dixon, and E. M. Jaffee
HER-2/neu Is a Tumor Rejection Target in Tolerized HER-2/neu Transgenic Mice
Cancer Res., July 1, 2000; 60(13): 3569 - 3576.
[Abstract] [Full Text]


Home page
J. Immunol.Home page
E. V. Fedoseyeva, F. Boisgerault, N. G. Anosova, W. S. Wollish, P. Arlotta, P. E. Jensen, S. J. Ono, and G. Benichou
CD4+ T Cell Responses to Self- and Mutated p53 Determinants During Tumorigenesis in Mice
J. Immunol., June 1, 2000; 164(11): 5641 - 5651.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
T. A. Colella, T. N.J. Bullock, L. B. Russell, D. W. Mullins, W. W. Overwijk, C. J. Luckey, R. A. Pierce, N. P. Restifo, and V. H. Engelhard
Self-Tolerance to the Murine Homologue of a Tyrosinase-Derived Melanoma Antigen: Implications for Tumor Immunotherapy
J. Exp. Med., April 3, 2000; 191(7): 1221 - 1232.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
B. Ludewig, A. F. Ochsenbein, B. Odermatt, D. Paulin, H. Hengartner, and R. M. Zinkernagel
Immunotherapy with Dendritic Cells Directed against Tumor Antigens Shared with Normal Host Cells Results in Severe Autoimmune Disease
J. Exp. Med., March 6, 2000; 191(5): 795 - 804.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. N. J. Bullock, T. A. Colella, and V. H. Engelhard
The Density of Peptides Displayed by Dendritic Cells Affects Immune Responses to Human Tyrosinase and gp100 in HLA-A2 Transgenic Mice
J. Immunol., March 1, 2000; 164(5): 2354 - 2361.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Hernandez, P. P. Lee, M. M. Davis, and L. A. Sherman
The Use of HLA A2.1/p53 Peptide Tetramers to Visualize the Impact of Self Tolerance on the TCR Repertoire
J. Immunol., January 15, 2000; 164(2): 596 - 602.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. T. Nugent, D. J. Morgan, J. A. Biggs, A. Ko, I. M. Pilip, E. G. Pamer, and L. A. Sherman
Characterization of CD8+ T Lymphocytes That Persist After Peripheral Tolerance to a Self Antigen Expressed in the Pancreas
J. Immunol., January 1, 2000; 164(1): 191 - 200.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Shimizu, S. Yamazaki, and S. Sakaguchi
Induction of Tumor Immunity by Removing CD25+CD4+ T Cells: A Common Basis Between Tumor Immunity and Autoimmunity
J. Immunol., November 15, 1999; 163(10): 5211 - 5218.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H. T. C. Kreuwel, D. J. Morgan, T. Krahl, A. Ko, N. Sarvetnick, and L. A. Sherman
Comparing the Relative Role of Perforin/Granzyme Versus Fas/Fas Ligand Cytotoxic Pathways in CD8+ T Cell-Mediated Insulin-Dependent Diabetes Mellitus
J. Immunol., October 15, 1999; 163(8): 4335 - 4341.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
E. M. Sotomayor, I. Borrello, E. Tubb, J. P. Allison, and H. I. Levitsky
In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance
PNAS, September 28, 1999; 96(20): 11476 - 11481.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
A. van Elsas, A. A. Hurwitz, and J. P. Allison
Combination Immunotherapy of B16 Melanoma Using Anti-Cytotoxic T Lymphocyte-Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation
J. Exp. Med., August 2, 1999; 190(3): 355 - 366.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. J. Molldrem, P. P. Lee, C. Wang, R. E. Champlin, and M. M. Davis
A PR1-Human Leukocyte Antigen-A2 Tetramer Can Be Used to Isolate Low-Frequency Cytotoxic T Lymphocytes from Healthy Donors That Selectively Lyse Chronic Myelogenous Leukemia
Cancer Res., June 1, 1999; 59(11): 2675 - 2681.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
D. J. Morgan, C. Kurts, H. T. C. Kreuwel, K. L. Holst, W. R. Heath, and L. A. Sherman
Ontogeny of T cell tolerance to peripherally expressed antigens
PNAS, March 30, 1999; 96(7): 3854 - 3858.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. Lustgarten, J. Marks, and L. A. Sherman
Redirecting Effector T Cells Through Their IL-2 Receptors
J. Immunol., January 1, 1999; 162(1): 359 - 365.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. Romieu, M. Baratin, M. Kayibanda, V. Lacabanne, M. Ziol, J.-G. Guillet, and M. Viguier
Cutting Edge: Passive But Not Active CD8+ T Cell-Based Immunotherapy Interferes with Liver Tumor Progression in a Transgenic Mouse Model
J. Immunol., November 15, 1998; 161(10): 5133 - 5137.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. M. Tempero, M. L. VanLith, K. Morikane, G. J. Rowse, S. J. Gendler, and M. A. Hollingsworth
CD4+ Lymphocytes Provide MUC1-Specific Tumor Immunity In Vivo That Is Undetectable In Vitro and Is Absent in MUC1 Transgenic Mice
J. Immunol., November 15, 1998; 161(10): 5500 - 5506.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
B. Minev, J. Hipp, H. Firat, J. D. Schmidt, P. Langlade-Demoyen, and M. Zanetti
Cytotoxic T cell immunity against telomerase reverse transcriptase in humans
PNAS, April 25, 2000; 97(9): 4796 - 4801.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1998 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1998 by The American Association of Immunologists, Inc. All rights reserved.